Gemcitabine Hydrochloride, Dasatinib, And Erlotinib Hydrochloride In Treating Patients With Pancreatic Cancer That Is Metastatic Or Cannot Be Removed By Surgery

Study Overview

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and dasatinib when given together with erlotinib hydrochloride in treating patients with pancreatic cancer that has spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dasatinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine hydrochloride and dasatinib together with erlotinib hydrochloride may kill more tumor cells.

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (also phase II recommended dose) of the combination of gemcitabine (gemcitabine hydrochloride), erlotinib (erlotinib hydrochloride) and dasatinib in patients with advanced pancreatic adenocarcinoma. SECONDARY OBJECTIVES: I. To determine the safety profile of the combination of gemcitabine, erlotinib and dasatinib. II. To evaluate the response rate and response duration of advanced pancreatic adenocarcinoma treated with dasatinib, erlotinib and gemcitabine. III. To determine progression-free survival and overall survival for this group of patients. IV. To determine the utility of advanced magnetic resonance imaging techniques to assess in vivo effects of therapy (changes in tumor vascularity, cellularity). V. To assess the use of serum markers as predictors of response and outcome. OUTLINE: This is a dose-escalation study of gemcitabine hydrochloride and dasatinib. Patients receive gemcitabine hydrochloride intravenously (IV) over 30-60 minutes on days 1, 8, and 15, and dasatinib orally (PO) once daily (QD) and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then every 4 weeks thereafter.

Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

DRUG: Dasatinib
DRUG: Erlotinib Hydrochloride
DRUG: Gemcitabine Hydrochloride

NCI-2012-01290
NCI-2012-01290 (REGISTRY Identifier) (REGISTRY: CTRP (Clinical Trial Reporting Program))
VICCGI1173
GI 1173
CDR0000738551
GI 1173 (OTHER Identifier) (OTHER: Vanderbilt University/Ingram Cancer Center)
9043 (OTHER Identifier) (OTHER: CTEP)
P30CA068485 (U.S. NIH Grant/Contract)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2012-08-07	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-03-20
First Submitted that Met QC Criteria 2012-08-07	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-03-21
First Posted (ACTUAL) 2012-08-09	Results First Posted N/A	Last Verified 2025-03

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Treatment (gemcitabine, dasatinib, erlotinib) Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	DRUG: Dasatinib Given PO DRUG: Erlotinib Hydrochloride Given PO DRUG: Gemcitabine Hydrochloride Given IV

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Treatment (gemcitabine, dasatinib, erlotinib)

Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

DRUG: Dasatinib

Given PO

DRUG: Erlotinib Hydrochloride

Given PO

DRUG: Gemcitabine Hydrochloride

Given IV

Primary Outcome Measures	Measure Description	Time Frame
Maximum tolerated dose of gemcitabine hydrochloride and dasatinib given together with erlotinib hydrochloride, determined by incidence of dose-limiting toxicity graded according to NCI CTCAE v 4.0		Up to 4 weeks after completion of study treatment

Secondary Outcome Measures	Measure Description	Time Frame
Overall survival (OS)	The OS curves will be estimated by the Kaplan-Meier method. Median OS and its 95% confidence intervals will be estimated.	The time from enrollment until the time of death due to any cause, assessed up to 6 years
Progression free survival (PFS)	The PFS curves will be estimated by the Kaplan-Meier method. Median PFS and its 95% confidence intervals will be estimated.	The time from enrollment until the first occurrence of radiographic or clinical evidence of disease progression or death due to any cause, assessed up to 6 years
Response rate, assessed according to RECIST	The response rate and its 95% confidence interval will be calculated using the exact binominal method.	Up to 6 years
Response duration	The response duration for the responders will be summarized using mean, median and standard deviation.	The time from when measurement criteria are met for complete response or partial response (whichever is first recorded) until the date that recurrent or progressive disease is objectively documented, assessed up to 6 years
Serious and other significant adverse events (AEs), graded according to NCI CTCAE v 4.0	The patient incidence of AEs will be summarized by preferred term, severity and relationship to study drug. Cross tabulations will be provided to summarize frequencies of abnormalities.	Up to 30 days after completion of study treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Cytologically or histologically confirmed pancreatic adenocarcinoma (excluding islet cell or ampullary tumors) that is metastatic or unresectable
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients may have received prior chemotherapy for advanced disease as long as it did not include gemcitabine; if patients received prior adjuvant therapy including gemcitabine, patients must be > 6 months from the last dose of gemcitabine; patients must have recovered from side effects of prior therapy to grade =< 1 as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0
Patients may have received prior radiation presuming > 4 weeks since last dose and measurable disease outside the radiation field
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
Anticipated life expectancy of greater than 3 months
Leukocytes >= 3,000/mcL
Absolute neutrophil count >= 1,500/mcL
Platelets >= 100,000/mcL
Total bilirubin < 2.5 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic pyruvate transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal OR =< 5 x institutional upper limit of normal when liver metastases are present
Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Ability to understand and the willingness to sign a written informed consent document
Patients must be able to swallow pills

Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia and neuropathy); no radiation is allowed on study
Patients who are receiving any other investigational agents
Major surgical procedure within 4 weeks of treatment
Patients with known brain metastases
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, erlotinib or gemcitabine
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinib
Patients with immune deficiency are excluded
Patients on potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and inhibitors
Malabsorption syndrome or other condition that would interfere with intestinal absorption
Other active malignancy (with the exception of locally treated non-melanoma skin cancers)
Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy
Patients may not have any clinically significant cardiovascular disease including the following:

Myocardial infarction or ventricular tachyarrhythmia within 6 months
Prolonged corrected QT (QTc) > 480 msec (Fridericia correction)
Known ejection faction less than institutional normal
Major conduction abnormality (unless a cardiac pacemaker is present)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Dana B Cardin, Vanderbilt University/Ingram Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record